These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 24833845

  • 1. Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
    Yuan H, Li AJ, Ma SL, Cui LJ, Wu B, Yin L, Wu MC.
    World J Gastroenterol; 2014 May 07; 20(17):4953-62. PubMed ID: 24833845
    [Abstract] [Full Text] [Related]

  • 2. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
    Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL, Chen PJ, Chen KF.
    Cell Death Dis; 2013 Feb 07; 4(2):e485. PubMed ID: 23392173
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH, Feng WC, Lu LC, Shao YY, Hsu CH, Cheng AL.
    Cancer Lett; 2016 Oct 10; 381(1):58-66. PubMed ID: 27431312
    [Abstract] [Full Text] [Related]

  • 4. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 5. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
    Chen CH, Chen MC, Wang JC, Tsai AC, Chen CS, Liou JP, Pan SL, Teng CM.
    Clin Cancer Res; 2014 Mar 01; 20(5):1274-1287. PubMed ID: 24520095
    [Abstract] [Full Text] [Related]

  • 6. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT, Liu YC, Chiang IT, Liu RS, Wang HE, Lin WJ, Hwang JJ.
    Int J Oncol; 2014 Jul 01; 45(1):177-88. PubMed ID: 24807012
    [Abstract] [Full Text] [Related]

  • 7. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
    Walker T, Mitchell C, Park MA, Yacoub A, Graf M, Rahmani M, Houghton PJ, Voelkel-Johnson C, Grant S, Dent P.
    Mol Pharmacol; 2009 Aug 01; 76(2):342-55. PubMed ID: 19483104
    [Abstract] [Full Text] [Related]

  • 8. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B, Wei W, Ma L, Yang B, Gill RM, Chua MS, Butte AJ, So S.
    Gastroenterology; 2017 Jun 01; 152(8):2022-2036. PubMed ID: 28284560
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
    Chen Y, Feng F, Gao X, Wang C, Sun H, Zhang C, Zeng Z, Lu Y, An L, Qu J, Wang F, Yang Y.
    Curr Cancer Drug Targets; 2015 Jun 01; 15(3):176-87. PubMed ID: 25714700
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
    Ishijima N, Kanki K, Shimizu H, Shiota G.
    Cancer Sci; 2015 May 01; 106(5):567-75. PubMed ID: 25683251
    [Abstract] [Full Text] [Related]

  • 18. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL.
    Clin Cancer Res; 2009 Sep 15; 15(18):5820-8. PubMed ID: 19737956
    [Abstract] [Full Text] [Related]

  • 19. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M, Chen C, Geng J, Han D, Wang T, Xie T, Wang L, Wang Y, Wang C, Lei Z, Chu X.
    Cancer Lett; 2017 Jul 10; 398():12-21. PubMed ID: 28377178
    [Abstract] [Full Text] [Related]

  • 20. Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
    D'Alessandro R, Refolo MG, Lippolis C, Giannuzzi G, Carella N, Messa C, Cavallini A, Carr BI.
    BMC Cancer; 2014 May 21; 14():351. PubMed ID: 24885890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.